# Versartis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/versartis

- Industry: Pharmaceuticals
- Headquarters: Redwood City, US
- Website: www.versartis.com
- Total disclosed funding: $113M
- Latest round: Series E (Feb 18, 2014)
- Investors on record: 7

## About

Versartis, Inc. is a biopharmaceutical company focused on developing innovative therapies for serious medical conditions, primarily targeting growth hormone deficiency and related disorders.Founded in 2008 in Redwood City, US, Versartis, Inc. specializes in developing treatments for growth hormone deficiency. The company went public in March 2014, raising USD 126 mn from its IPO. The current CEOs are Gail McIntyre and Jeffrey Cleland.Versartis, Inc. primarily offers therapeutic solutions aimed at addressing growth hormone deficiencies. Their flagship product focuses on enhancing growth hormone levels in affected patients, with applications in both pediatric and adult populations. The company’s products cater to healthcare providers and patients globally, supporting a range of therapeutic needs.In the most recent year, 2017, Versartis, Inc. reported revenue of USD 40.00 mn, alongside an EBITDA loss of USD 84.17 mn.Following its IPO on March 21, 2014, which raised USD 126 mn, Versartis, Inc. aims to expand its product offerings and enter new markets within the biopharmaceutical sector. The company plans to invest in the development of additional therapies aimed at addressing growth disorders while seeking to penetrate emerging markets in Asia and Europe by 2025. The funds from the IPO will be utilized to support these initiatives, ensuring continued growth and innovation in their therapeutic portfolio.

## Funding rounds

- Series E, Feb 18, 2014, $55M — Sofinnova Investments, Aisling Capital, New Leaf Venture Partners, Advent Life Sciences
- Series D, Feb 4, 2014, $10M — Index Ventures, Sofinnova Investments, Advent Venture Partners, Aisling Capital, New Leaf Venture Partners
- Series D, Oct 10, 2013, $10M — Index Ventures, Sofinnova Investments, Aisling Capital, New Leaf Venture Partners, Amunix Pharmaceuticals, Inc., Advent Life Sciences
- Series C, Jan 25, 2013, $13M — Index Ventures, Aisling Capital, New Leaf Venture Partners, Advent Life Sciences
- Series B, Feb 16, 2011, $14M — Index Ventures, New Leaf Venture Partners, Amunix Pharmaceuticals, Inc., Advent Life Sciences
- Series A, Jun 2, 2009, $11M — Index Ventures

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series B, Series C, Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C, Series D, Series E
- Amunix Pharmaceuticals, Inc. — Series B, Series D
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B, Series C, Series D, Series E
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C, Series D, Series E
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series D, Series E
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series D